Human IL-17 F(Interleukin 17F) ELISA Kit

TH17 is a subset of CD4+T cells. Comparing to common asthma patients, there are more TH17 cells in the respiratory systems of the patients with severe asthma. TH17 cells are mainly adjusted by IL23 to produce IL17A and IL17F, which act on the epithelial cells and cause severe asthma. However, the TH17 function in severe asthma as a driving mechanism of neutrophilic inflammation is not yet fully understood and deserves further study. However, it is very difficult to describe the interactions between TH17 and other cells using mathematics equations due to the high complexity of immunity system. In order to explore the TH17 function in severe asthma, we used BIS (Basic Immune Simulator) platform to simulate TH17 models, and compared DC (Dendritic Cell) models with TH17 models. We studied the interaction between innate immune and adaptive immune cells, which was resulted from TH17 cells. The simulation results for the TH17 models are consistent with clinical data, which suggests that DC-IL23-TH17 axis might be the path of causing severe asthma. Our simulation studies support a role for TH17 in severe asthma, and hence it could be taken as a new target candidate for clinical treatment of severe asthma. (C) 2012 Elsevier Ltd. All rights reserved.

Background: Recent studies have revealed the pivotal role of Th17 cells and interleukin-17 (IL-17) in plaque psoriasis development and treatment outcome. The IL-17 family consists of 6 structurally related cytokines (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F), of which IL-17A and IL-17F mediate similar biological effects. Objectives: The aim of this study was to evaluate an association between the IL 17A (-197G>A; rs2275913) and IL17F (rs763780: T>C; rs11465553: G>A; rs2397084:T>C) polymorphisms with psoriasis susceptibility as well as response to topical and combined topical with narrow-band ultraviolet B (NB-UVB) therapy in a Polish population. Methods: Association study involving 407 psoriasis patients and 205 healthy controls. Treatment efficacy was analyzed in 207 patients with mild psoriasis (Psoriasis Area and Severity Index; PASI 3-12) and moderate psoriasis (PASI 12-18), who were randomly subjected to topical or combined topical and NB-UVB treatment. The polymorphisms were evaluated by RT-PCR. Results: No statistically significant differences between psoriasis patients and controls were found in the frequency of the evaluated IL and IL17F genotypes and haplotypes. The IL17A or IL17F polymorphisms were not associated with treatment outcome measures: efficacy of treatment at the eighth week of the study and PASI change after topical or combined topical and NB-UVB therapy. However, IL17F rs2397084 variant allele C carriers required a significantly higher number of NB-UVB irradiations in comparison to TT homozygotes (15.5 +/- 11.4 vs. 11.1 +/- 11.9, p = 0.047) to produce a positive clinical response. Conclusion: It can be stated that the IL17A and IL17F polymorphisms are not markers of susceptibility to psoriasis. However, the IL17F polymorphism may affect the response to NB-UVB therapy. (C) 2016 S. Karger AG, Basel